Grifols is driven by the biopharmaceutical business to increase profit to €73 million

BarcelonaGrifols earned 73 million euros in the first quarter, 21.9% more than in the same period last year. As reported by the Catalan multinational in plasma-derived medicines, between January and March it registered a turnover of 1,700 million euros.

At constant exchange rates, it raises turnover by 3.3%. The same phenomenon is observed in EBITDA (earnings before interest, taxes, and amortization), which grows by eight tenths at constant exchange rates, but falls by about 19 million euros when translated into euros. It should be remembered that more than half of the Catalan company's income comes from the United States.

Compared to the same period in 2025, Grifols has improved free cash flow by 30 million euros, one of the most relevant variables in the eyes of investors, as it details the pharmaceutical company's ability to face its still abundant debt. On these results, the company will propose to the shareholders' meeting the definitive approval of the dividend for 2025.

The biopharmaceutical segment grows

The protagonist of Grifols' business activity has once again been the biopharmaceutical segment, which has grown by 6.8% at constant exchange rates. The momentum has been concentrated in immunoglobulin solutions, which have risen more than 15.3% if exchange rates are ignored. On the other hand, proteins and alpha-1 medications registered a setback of 7.4%. The company points to a "more demanding comparative base" in the first quarter of 2025, despite the market anticipating that increased competition in the segment could harm the Catalan company's activity.

Regarding these accounts, the pharmaceutical company's CEO, Nacho Abia, has celebrated "a performance in line with expectations" to start 2026. According to the chief executive, Grifols would be on the right track to "meet the results guidance for the entirety of 2026, as momentum is gained during the fiscal year." For his part, the CFO, Rahul Srinivasan, has highlighted the immunoglobulin franchise's ability to accelerate results. Furthermore, he points to "a strengthening of the capital structure" following the refinancing with favorable terms of the 2027 debt maturities.